Company Summary - Yong'an Pharmaceutical (SZ 002365) announced that several directors and senior management, including Hong Rengui, Fang Xiquan, Wang Zhihua, Xiong Shengjie, and Li Shaobo, plan to reduce their holdings by up to approximately 240,000 shares within three months, which represents 0.0799% of the total share capital [1] - The company’s current market capitalization is 5.1 billion yuan [1] Revenue Composition - For the first half of 2025, Yong'an Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 64.14%, health food for 24.67%, chemical manufacturing for 10.88%, and other businesses for 0.32% [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) announced that several directors and senior management plan to reduce their shareholding in the company through centralized bidding transactions within three months after a 15 trading day period following the announcement [1] Group 1: Shareholding Details - A total of 942,000 shares are held by the directors and senior management, representing 0.3197% of the total share capital and 0.3258% when excluding shares in the company's repurchase special account [1] - The planned reduction will not exceed 235,400 shares, which is 0.0799% of the total share capital and 0.0814% when excluding shares in the company's repurchase special account [1] Group 2: Control Implications - The share reduction will not lead to a change in the company's control [1]

证券日报网讯永安药业11月3日在互动平台回答投资者提问时表示，截至2025年10月20日，公司股东人 数为59707户。 （文章来源：证券日报） ...

Core Viewpoint - Yong'an Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 118.32%, but recent declines in the short term raise questions about future performance [1][2]. Group 1: Stock Performance - On October 31, Yong'an Pharmaceutical's stock rose by 2.01%, reaching 17.23 CNY per share, with a total market capitalization of 5.077 billion CNY [1]. - The stock has experienced a decline of 0.75% over the last five trading days, 1.15% over the last 20 days, and 12.05% over the last 60 days [1]. - The company has appeared on the trading leaderboard 30 times this year, with the most recent appearance on July 21, where it recorded a net buy of -289 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Yong'an Pharmaceutical reported a revenue of 577 million CNY, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 25.496 million CNY, down 58.78% year-on-year [2]. - The company has distributed a total of 401 million CNY in dividends since its A-share listing, with 87.665 million CNY distributed over the last three years [3]. Group 3: Company Overview - Yong'an Pharmaceutical, established on June 18, 2001, and listed on March 5, 2010, is primarily engaged in the research, production, and sales of taurine products, which account for 64.14% of its main business revenue [1]. - The company operates within the pharmaceutical and biological sector, specifically in chemical pharmaceuticals and raw materials, and is involved in various concept sectors including pet economy and e-commerce [2].

Core Viewpoint - The company has disclosed its third-quarter financial report, confirming the accuracy and completeness of the information provided, and has made significant changes in its corporate structure and management [2][12]. Financial Data - The third-quarter financial report has not been audited [11]. - The company reported no need for retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - As of the reporting period, the company holds 5,537,350 shares in its repurchase account, accounting for 1.88% of the total shares, ranking fourth among all shareholders [5]. - The top ten shareholders and their shareholding status have not changed due to any lending or borrowing activities [5]. Corporate Governance Changes - The company has amended its business scope and increased the number of board members from six to seven, adding one employee representative director and one vice chairman [6]. - The supervisory board has been abolished, with its functions transferred to the audit committee of the board [6]. Acquisition and Investment - The company has acquired 49.20% of the shares from minority shareholders of Hubei Ling'an Technology Co., Ltd. for 27 million yuan, resulting in full ownership of the subsidiary [6][7]. Management Changes - The company has elected Chen Zidi as the vice chairman and appointed several new senior management personnel, including Dong Shihao as vice general manager [13]. Legal Matters - The company is involved in a patent infringement lawsuit in the U.S. but received a favorable ruling, with the plaintiff required to compensate for some legal fees [9].

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders of the listed company was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, reflecting a significant decline of 86.17% year-on-year [1]

Core Viewpoint - Yong'an Pharmaceutical (002365.SZ) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved an operating income of 577 million yuan, representing a year-on-year decrease of 6.72% [1] - The net profit attributable to shareholders was 25.5 million yuan, down 58.78% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 5.18 million yuan, a decrease of 86.17% year-on-year [1] - Basic earnings per share were reported at 0.0881 yuan [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-62 潜江永安药业股份有限公司 第七届董事会第十次临时会议决议公告 根据公司经营发展需要，同意聘任董世豪先生为公司副总经理，聘任彭波先 生、吴旭先生、黄宁军先生为公司高级管理人员，任期自本次董事会审议通过之 日起至第七届董事会任期届满之日止。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第七届董事会第十次临时 会议的会议通知于 2025 年 10 月 24 日以书面、电话、传真、电子邮件等形式送 达公司全体董事，会议于 2025 年 10 月 29 日在公司会议室以通讯方式召开，本 次会议应参与审议表决董事 7 人，实际参与审议表决董事 7 人。本次会议由董事 长陈勇先生主持，会议的召集和召开符合《公司法》及《公司章程》的规定。会 议以书面记名投票方式逐项表决，通过了如下决议： 一、审议通过《关于选举第七届董事会副董事长的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 根据《公司章程》相关规定，同意选举董事陈子笛先生为公司第七届董事会 ...

Group 1 - The core viewpoint of the article highlights that Yong'an Pharmaceutical reported a revenue of 210 million yuan in the third quarter, representing a year-on-year increase of 8.75% [1] - The net profit for the third quarter was 13.0005 million yuan, showing a year-on-year growth of 38.75% [1] Group 2 - For the first three quarters, the total revenue was 577 million yuan, which reflects a year-on-year decline of 6.72% [1] - The net profit for the first three quarters was 25.4963 million yuan, indicating a significant year-on-year decrease of 58.78% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥209,771,612.84, representing an increase of 8.75% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2025 was ¥13,000,535.84, a significant increase of 38.75% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥2,899,082.25, up 91.82% compared to the previous year[5]. - Total operating revenue for the current period was ¥577,148,711.33, a decrease of 6.7% from ¥618,715,718.75 in the previous period[24]. - Net profit for the current period was ¥16,342,120.79, down 72.2% from ¥58,799,695.42 in the previous period[25]. - The profit attributable to the parent company's shareholders was ¥25,496,259.56, a decrease of 58.8% compared to ¥61,855,243.42 in the previous period[25]. - Basic earnings per share for the current period was ¥0.0881, down from ¥0.2105 in the previous period[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,262,430,873.84, a decrease of 2.00% from the end of the previous year[5]. - Total assets decreased to ¥2,262,430,873.84 from ¥2,308,602,905.85, reflecting a decline of 2.0%[23]. - Total liabilities decreased to ¥247,199,813.94 from ¥266,545,677.53, a reduction of 7.3%[23]. - Total equity attributable to the parent company was ¥1,976,432,019.92, down from ¥1,993,780,889.08, a decrease of 0.9%[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥98,664,888.88, an increase of 5.76%[5]. - Operating cash flow for the current period is ¥98,664,888.88, an increase of 0.4% compared to ¥93,294,328.83 in the previous period[26]. - Total cash inflow from investment activities decreased to ¥779,294,652.40 from ¥938,272,584.94, a decline of approximately 16.9%[26]. - Net cash flow from investment activities is -¥110,081,416.72, improving from -¥145,855,877.36 in the previous period[26]. - Cash inflow from financing activities decreased to ¥15,000,000.00 from ¥20,600,000.00, a decline of 27.0%[27]. - Net cash flow from financing activities is -¥76,004,051.88, worsening from -¥54,723,270.65 in the previous period[27]. - The net increase in cash and cash equivalents for the current period is -¥85,570,105.23, compared to -¥101,078,767.21 in the previous period[27]. - The ending balance of cash and cash equivalents is ¥234,835,187.73, up from ¥193,149,436.01 in the previous period[27]. - Cash received from the sale of goods and services is ¥604,670,318.15, down 8.2% from ¥658,699,780.62[26]. - Total cash outflow from operating activities is ¥548,206,206.09, a decrease from ¥634,892,089.71, reflecting a reduction of approximately 13.6%[26]. - Cash received from tax refunds is ¥18,198,428.70, down from ¥21,847,313.41, a decline of about 16.1%[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 57,923[12]. - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12]. - The company repurchased 5,537,350 shares, representing 1.88% of the total shares, ranking fourth among all shareholders[13]. - The top ten shareholders include Huanggang Yong'an Pharmaceutical Co., Ltd. with a 2.82% stake, amounting to 8,313,532 shares[12]. - The company completed a share reduction plan where the controlling shareholder reduced their stake by 2,632,300 shares, accounting for 0.8933% of the total share capital[16]. Corporate Actions - The company approved the acquisition of 49.20% equity from minority shareholders of Hubei Ling'an Technology Co., Ltd. for a total of RMB 27 million[15]. - Following the acquisition, the company will hold 100% equity in Ling'an Technology, with no changes to the consolidated financial statement scope[15]. - The company plans to adjust its business scope and increase the board members from 6 to 7, adding one employee representative director and one vice chairman[14]. - The company will abolish the supervisory board, transferring its powers to the audit committee of the board[14]. - The company completed the necessary business registration changes and obtained a new business license on October 21, 2025[14]. Legal and Compliance - The company is actively monitoring the progress of a patent infringement lawsuit in the U.S. where it was previously cleared of any infringement claims[17]. Operational Challenges - The company experienced a 73.63% decrease in operating profit, attributed to a decline in sales volume and price of its main product, taurine[10]. - Sales expenses increased by 167.48% year-on-year, mainly due to increased promotion and advertising costs for the company's self-owned brand products[9]. - The company has reported a significant decrease in cash reserves, which may impact future operational liquidity[21].